2019

Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma 

#02534 Grant Period: July 1, 2019 – December 31, 2024

Canine hemangiosarcoma is a largely incurable cancer in dogs, and treatment approaches to improve outcomes have remained relatively stagnant over the past few decades. Treatment remains a challenge partly because the cancer is frequently detected at an advanced stage and because these tumors are often resistant to chemotherapies.

Read more

Is Gut Dysbiosis Associated with Canine Idiopathic Epilepsy

#02561 Grant Period: February 1, 2019 – December 31, 2023

Idiopathic epilepsy is the most common chronic nervous system disorder of dogs. Its cause is poorly understood, but is believed to involve genetic and environmental factors. Treatment with anti-seizure drugs remains the standard of care. However, approximately one-third of dogs fail to achieve satisfactory seizure control, highlighting the need to investigate factors that may influence disease course.

Read more